Publications by authors named "Steve Brough"

Claim this Profile
S
Structure-activity relationships of 2-pyrimidinecarbohydrazides as utrophin modulators for the potential treatment of Duchenne muscular dystrophy.
Maria Chatzopoulou, Daniel Conole, Enrico Emer, Jessica A Rowley, Nicky J Willis, Steve Brough

Bioorg Med Chem· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of Routine Intraoperative Ureteral Frozen Section Analysis at Radical Cystectomy: Outcomes from a Regional Australian Center.
Joanne Tang, Weranja Ranasinghe, Janice Cheng, Sabiena Van Es, Mike Monsour, Steve Brough

Curr Urol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981.
Tim Luker, Roger Bonnert, Steve Brough, Anthony R Cook, Mark R Dickinson

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching between agonists and antagonists at CRTh2 in a series of highly potent and selective biaryl phenoxyacetic acids.
Tim Luker, Roger Bonnert, Jerzy Schmidt, Carol Sargent, Stuart W Paine, Steve Brough

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors.
Andrew Baxter, Steve Brough, Anne Cooper, Eike Floettmann, Steve Foster

Bioorg Med Chem Lett· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hit-to-Lead studies: the discovery of potent adamantane amide P2X7 receptor antagonists.
Andrew Baxter, Janice Bent, Keith Bowers, Martin Braddock, Steve Brough

Bioorg Med Chem Lett· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists.
Andrew Baxter, Colin Bennion, Janice Bent, Kerry Boden, Steve Brough

Bioorg Med Chem Lett· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis